Principal Investigator
Christopher van Dyck, MD
Yale University
- 2 trials
- 1 compound
Therapeutic focus
- Alzheimer Disease
- Alzheimer's Disease
All trials (2)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT03493282 | Phase 1/2 | Completed | Zervimesine | Cognition Therapeutics, Inc. |
| NCT01864655 | Phase 1 | Completed | — | Stephen M. Strittmatter |
Compounds studied
Trial sites (1)
- New Haven, Connecticut, United States
Investigator and site data mirrored fromClinicalTrials.gov (public domain).